BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) — Matinas Bio, a clinical-stage biopharmaceutical company focused on delivering breakthrough therapies using lipid nanocrystal (LNC) platform delivery technology. Pharma Holdings, Inc. (NYSE America: MTNB) has made the following announcement:new in vitro Data demonstrating the use of LNCs for the delivery of small molecule oligonucleotides was presented yesterday at a poster session at TIDES USA 2024: Oligo Nuclear & Peptide Therapeutics, a hybrid in-person/virtual conference in Boston.
Poster “Intracellular delivery of small oligonucleotides using lipid nanocrystals (LNCs)”: in vitro Research” was presented by Dr. Hui Liu, Chief Technology Officer of Matinas and is available here.the poster speaks in vitro Studies have demonstrated avid uptake of LNC formulations of small oligonucleotides of various cytokine targets in murine macrophages, with up to 70% gene knockdown observed for each targeted cytokine.
“While there is growing interest in small molecule oligonucleotides in multiple therapeutic areas, a major barrier to their use is systemic delivery, which can lead to reduced toxicity and immunogenicity.” said Dr. Liu. “these in vitro Studies have shown that our LNCs can successfully encapsulate and protect ASOs, siRNAs, and other small oligonucleotides even when exposed to gastric fluids, and deliver them to a variety of cells with demonstrable bioactivity. was shown. These properties make LNCs a very promising oral drug delivery platform for future applications requiring oral delivery of small oligonucleotides. ”
About Matinas Biopharma
Matinas BioPharma is a biopharmaceutical company focused on delivering breakthrough therapeutics using lipid nanocrystal (LNC) platform delivery technology.
Matinas' lead LNC-based therapy is MAT2203, an oral formulation of the broad-spectrum antifungal drug amphotericin B. It is very powerful, but can be seriously toxic. Matinas' LNC platform provides oral administration of amphotericin B without the significant nephrotoxicity associated with IV-administered formulations. The combination of comparable fungicidal activity and targeted delivery may reduce the risk of toxicity and create an ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients with cryptococcal meningitis, meeting the primary endpoint and achieving favorable survival. MAT2203 was further evaluated in a single phase 3 registration trial (the “ORALTO” trial) as an oral step-down monotherapy after treatment with AmBisome® (liposomal amphotericin B), with limited invasive compared with standard treatment for patients with sexual aspergillosis. treatment options.
In addition to MAT2203, preclinical and clinical data show that this new technology supports safe and effective intracellular delivery of both small molecules and larger, more complex molecular cargoes, including small oligonucleotides such as ASOs and siRNAs. It has demonstrated that it has the potential to provide solutions to the many challenges of achieving. Due to the combination of its unique mechanism of action and flexibility in routes of administration (including oral), Matinas' his LNC technology may be recommended as the next generation orally available intracellular drug delivery platform. . For more information, please visit www.matinasbiopharma.com.
Forward-looking statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. This includes with respect to our business activities, our strategy and plans, the future development of our product candidates, including MAT2203, and our capabilities. In order to identify and pursue development, licensing and partnership opportunities for our products, including MAT2203, or to provide platform delivery technology on favorable terms, we may rely on or rely on any necessary regulatory approvals or Ability to Obtain Other Forward-Looking Statements. to future events or situations. All statements other than statements of historical fact may be forward-looking statements. Forward-looking statements include words such as “expects,” “anticipates,” “intends,” “plans,” “may,” “believes,” “estimates” and similar expressions. It is included. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. It is. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to continue as a going concern and our ability to obtain additional capital to meet our liquidity needs on acceptable terms. Affected by certainty. additional capital required to complete clinical trials of our product candidates; our ability to successfully complete research, further development and commercialization of our product candidates; Uncertainty inherent in clinical testing. the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect our intellectual property; loss of executive officers, key personnel or consultants; competition; changes in the regulatory environment or the imposition of regulations affecting our products; and other factors listed under “Risk Factors” in our SEC filings (such as Forms 10-K, 10-Q, and 8-K). Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as required by law, we undertake no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. I am not responsible. All of Matinas BioPharma's product candidates are in the development stage and are not available for sale or use.
Investor contact information
LHA Investor Information
jody kane
Jcain@lhai.com
310-691-7100